SNGX News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

SN

Mkt Cap

$7.7M

Volume

216.80K

Next Earnings

November 6th

Chart Financials Earnings News About Insider Filings

Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola VaccineSoligenix (NASDAQ: SNGX) announced it is applying for vaccine development funding from the Coalition for Epidemic Preparedness Innovations (CEPI) for a Bundibugyo virus vaccine. The company, in collaboration with University of Hawaiʻi researchers, has developed thermostable filovirus vaccines that demonstrated up to 100% protection in non-human primates. The application leverages Soligenix's ThermoVax platform technology and addresses the ongoing Bundibugyo outbreak in the Democratic Republic of Congo and Uganda.Benzinga · Jun 8, 2026

Soligenix (SNGX) Stock Soars 72% On ThermoVax Platform Promise Amid Ebola Outbreak Caused By Bundibugyo VirusSoligenix shares surged 72% after announcing its ThermoVax platform can rapidly develop a vaccine for Bundibugyo virus, addressing a WHO-declared public health emergency in the Democratic Republic of Congo. The company's thermostabilized vaccine technology demonstrated 100% protection in non-human primates and has FDA Orphan Drug Designations for Sudan and Marburg viruses, providing market exclusivity and clinical trial funding.Benzinga · May 27, 2026

Cutaneous T-Cell Lymphoma Clinical Trial Pipeline Accelerates as 30+ Pharma Companies Rigorously Developing Drugs for Market Entry | DelveInsightOver 30 pharmaceutical companies are actively developing more than 30 pipeline drugs for cutaneous T-cell lymphoma (CTCL), a rare non-Hodgkin lymphoma affecting the skin. Key players including Prescient Therapeutics, Innate Pharma, and others are advancing promising therapies with various mechanisms of action through clinical trials. The market is projected to grow steadily driven by increasing adoption of targeted and immunotherapies, though limited patient populations and high treatment costs remain challenges.GlobeNewswire Inc. · May 21, 2026

The Psoriasis Clinical Trial Pipeline Boom as 90+ Companies are in the Race for Better Treatments | DelveInsightOver 90 pharmaceutical companies are actively developing more than 100 pipeline psoriasis drugs across various clinical stages. Key players including Takeda, Can-Fite BioPharma, Oruka Therapeutics, and others are advancing promising therapies with novel mechanisms of action such as TYK2 inhibitors and IL-23 inhibitors. Recent developments include positive Phase III results from Alumis and Takeda, and regulatory progress from multiple companies, indicating robust innovation in the psoriasis treatment landscape.GlobeNewswire Inc. · Apr 14, 2026

Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and TherapySoligenix announced positive clinical results from a comparative study showing HyBryte™ (synthetic hypericin) demonstrated more rapid and robust treatment response compared to Valchlor® (mechlorethamine) for cutaneous T-cell lymphoma treatment. The study showed 60% of HyBryte™ patients achieved treatment success versus 20% of Valchlor® patients at 12 weeks, with HyBryte™ showing superior safety profile. The FDA awarded a $2.6 million Orphan Products Development grant to the University of Pennsylvania to support expanded treatment evaluation.Benzinga · Apr 2, 2026

Soligenix Announces Recent Accomplishments and Year End 2025 Financial ResultsSoligenix reported zero revenues for 2025 and a net loss of $11.1 million as the company advances its rare disease pipeline. Key upcoming milestones include an interim analysis in Q2 2026 and top-line results in H2 2026 from the HyBryte Phase 3 CTCL trial. The company ended 2025 with $7.9 million in cash and is exploring strategic options including partnerships and financing to extend runway into Q4 2026.Benzinga · Mar 31, 2026

Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçet's DiseaseSoligenix announced that the European Commission has granted orphan drug designation to dusquetide (SGX945) for treating Behçet's Disease, following positive Phase 2a clinical results. The designation provides 10 years of marketing exclusivity in the EU. SGX945 previously received orphan drug and fast track designations from the FDA. The Phase 2a study showed 40% improvement in ulcer reduction compared to 37% for the approved drug apremilast, with no treatment-related adverse events.Benzinga · Mar 26, 2026

HyBryte™ Treatment Results to be Presented at US Cutaneous Lymphoma Consortium Annual Workshop 2026Soligenix announced that positive clinical trial results for HyBryte™ (synthetic hypericin), a photodynamic therapy for cutaneous T-cell lymphoma (CTCL), will be presented at the US Cutaneous Lymphoma Consortium Workshop in March 2026. The presentations will highlight favorable comparisons to Valchlor® and real-world treatment outcomes. Additionally, the FDA awarded a $2.6 million Orphan Products Development grant to the University of Pennsylvania to support expanded evaluation of HyBryte™ for early-stage CTCL treatment.Benzinga · Mar 23, 2026

IBN Announces Latest Episode of The BioMedWire Podcast Featuring the Return of Dr. Christopher Schaber, CEO of Soligenix Inc.Soligenix Inc. (NASDAQ: SNGX) announced an upcoming interim analysis of its Phase 3 FLASH2 study for HyBryte™ in treating cutaneous T-cell lymphoma. CEO Dr. Christopher Schaber reported a blinded aggregate response rate of 48% at the 50-patient mark, significantly exceeding the conservatively assumed 25% threshold. The company expects interim results this quarter and top-line data in the second half of 2026, which could represent transformational inflection points for commercialization.GlobeNewswire Inc. · Mar 19, 2026

Soligenix Announces SGX945 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory AgencySoligenix announced that SGX945 (dusquetide) has received Promising Innovative Medicine (PIM) designation from the UK's MHRA for treating Behçet's Disease. This designation is a prerequisite for inclusion in the UK Early Access to Medicines Scheme (EAMS), allowing severely ill patients earlier access to the experimental treatment. Phase 2a data showed SGX945 achieved a 40% improvement in ulcer reduction compared to placebo, comparable to the approved drug apremilast, with better tolerability and no treatment-related adverse events.Benzinga · Mar 10, 2026

SN

SNGXSoligenix, Inc. Common Stock

SNGX

Pay with—

Available Balance0.00

Your PositionYou don't own any SNGX yet.

Related Tickers

Earnings